Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
about
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies.The application of mass spectrometry to leukemia drug discovery.D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization.
P2860
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pretreatment d-2-hydroxyglutar ...... utated acute myeloid leukemia.
@en
type
label
Pretreatment d-2-hydroxyglutar ...... utated acute myeloid leukemia.
@en
prefLabel
Pretreatment d-2-hydroxyglutar ...... utated acute myeloid leukemia.
@en
P2093
P2860
P50
P356
P1433
P1476
Pretreatment d-2-hydroxyglutar ...... mutated acute myeloid leukemia
@en
P2093
G Ehninger
T Bochtler
P2860
P2888
P304
P356
10.1038/LEU.2015.317
P577
2015-11-19T00:00:00Z
P6179
1020035580